tetano
Editor, Senior Moderator
Can J Public Health
. 2022 Apr 5.
doi: 10.17269/s41997-022-00622-y. Online ahead of print.
Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study
Antoine Lewin[SUP] 1 2 [/SUP], Gaston De Serres[SUP] 3 4 [/SUP], Yves Grégoire[SUP] 5 [/SUP], Josée Perreault[SUP] 5 [/SUP], Mathieu Drouin[SUP] 5 [/SUP], Marie-Josée Fournier[SUP] 5 [/SUP], Tony Tremblay[SUP] 5 [/SUP], Julie Beaudoin[SUP] 6 [/SUP], Amélie Boivin[SUP] 1 [/SUP], Guillaume Goyette[SUP] 7 8 [/SUP], Andrés Finzi[SUP] 7 8 [/SUP], Renée Bazin[SUP] 5 [/SUP], Marc Germain[SUP] 5 [/SUP], Gilles Delage[SUP] 1 [/SUP], Christian Renaud[SUP] 9 [/SUP]
Affiliations
Abstract
in English, French
Objectives: We previously estimated the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies following the first pandemic wave at 2.23% in Québec, Canada. Following the much bigger second wave in fall 2020 and early 2021, we estimated the seroprevalence of anti-SARS-CoV-2 in Québec during the first months of 2021.
Methods: Blood samples from regular, asymptomatic (for ≥ 14 days) donors were collected between January 25, 2021 and March 11, 2021. Anti-SARS-CoV-2 seropositivity was assessed using an enzyme-linked immunosorbent assay that captures antibodies directed against the receptor binding domain of the SARS-CoV-2 spike (and hence cannot discriminate between infection- and vaccine-induced seropositivity). Seroprevalence estimates were adjusted for regional distribution, age, and sex.
Results: Samples from 7924 eligible donors were analyzed, including 620 (7.8%) vaccinated donors and 7046 (88.9%) unvaccinated donors (vaccination status unknown for 258 (3.3%) donors). Overall, median age was 51 years; 46.4% of donors were female. The adjusted seroprevalence was 10.5% (95% CI = 9.7-11.3) in the unvaccinated population and 14.7% (95% CI = 13.8-15.6) in the overall population. Seroprevalence gradually decreased with age and was higher among donors who self-identified as having a racial/ethnic background other than white, both in the overall and in the unvaccinated populations.
Conclusion: The seroprevalence of SARS-CoV-2 antibodies significantly increased in Québec since spring 2020, with younger persons and ethnic minorities being disproportionately affected. When compared with the cumulative incidence rate reported by public health authorities (i.e., 3.3% as of March 11, 2021), these results suggest that a substantial proportion of infections remain undetected despite improvements in access to COVID-19 testing.
Keywords: COVID-19; Prevalence; Public health surveillance; Serology.
. 2022 Apr 5.
doi: 10.17269/s41997-022-00622-y. Online ahead of print.
Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study
Antoine Lewin[SUP] 1 2 [/SUP], Gaston De Serres[SUP] 3 4 [/SUP], Yves Grégoire[SUP] 5 [/SUP], Josée Perreault[SUP] 5 [/SUP], Mathieu Drouin[SUP] 5 [/SUP], Marie-Josée Fournier[SUP] 5 [/SUP], Tony Tremblay[SUP] 5 [/SUP], Julie Beaudoin[SUP] 6 [/SUP], Amélie Boivin[SUP] 1 [/SUP], Guillaume Goyette[SUP] 7 8 [/SUP], Andrés Finzi[SUP] 7 8 [/SUP], Renée Bazin[SUP] 5 [/SUP], Marc Germain[SUP] 5 [/SUP], Gilles Delage[SUP] 1 [/SUP], Christian Renaud[SUP] 9 [/SUP]
Affiliations
- PMID: 35380364
- DOI: 10.17269/s41997-022-00622-y
Abstract
in English, French
Objectives: We previously estimated the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies following the first pandemic wave at 2.23% in Québec, Canada. Following the much bigger second wave in fall 2020 and early 2021, we estimated the seroprevalence of anti-SARS-CoV-2 in Québec during the first months of 2021.
Methods: Blood samples from regular, asymptomatic (for ≥ 14 days) donors were collected between January 25, 2021 and March 11, 2021. Anti-SARS-CoV-2 seropositivity was assessed using an enzyme-linked immunosorbent assay that captures antibodies directed against the receptor binding domain of the SARS-CoV-2 spike (and hence cannot discriminate between infection- and vaccine-induced seropositivity). Seroprevalence estimates were adjusted for regional distribution, age, and sex.
Results: Samples from 7924 eligible donors were analyzed, including 620 (7.8%) vaccinated donors and 7046 (88.9%) unvaccinated donors (vaccination status unknown for 258 (3.3%) donors). Overall, median age was 51 years; 46.4% of donors were female. The adjusted seroprevalence was 10.5% (95% CI = 9.7-11.3) in the unvaccinated population and 14.7% (95% CI = 13.8-15.6) in the overall population. Seroprevalence gradually decreased with age and was higher among donors who self-identified as having a racial/ethnic background other than white, both in the overall and in the unvaccinated populations.
Conclusion: The seroprevalence of SARS-CoV-2 antibodies significantly increased in Québec since spring 2020, with younger persons and ethnic minorities being disproportionately affected. When compared with the cumulative incidence rate reported by public health authorities (i.e., 3.3% as of March 11, 2021), these results suggest that a substantial proportion of infections remain undetected despite improvements in access to COVID-19 testing.
Keywords: COVID-19; Prevalence; Public health surveillance; Serology.